BrainsWay invests $2.3 million in Axis mental health services provider

BURLINGTON, Mass. and JERUSALEM - BrainsWay Ltd. (NASDAQ & TASE:BWAY) announced Wednesday it has entered into a strategic equity financing agreement with Axis Management Company, Inc., a management services organization for mental health clinics in Colorado.

Under the agreement, BrainsWay will invest $2.3 million initially with a potential additional $1 million based on milestones, acquiring a minority position in Axis in the form of a preferred, annually compounding security. The deal includes a redemption mechanism for the shares.

This investment follows BrainsWay’s previous stake in Stella and forms part of the company’s initiative to increase access to mental health treatments, including its Deep Transcranial Magnetic Stimulation (Deep TMS) therapy.

"Our minority-stake investment in Axis is part of BrainsWay’s broader initiative to accelerate access to and awareness of innovative mental health treatments," said Hadar Levy, Chief Executive Officer of BrainsWay, according to the press release. InvestingPro analysis reveals the company’s strong financial health with an overall score of "GREAT," suggesting solid fundamentals supporting its expansion strategy. For detailed insights and additional ProTips about BWAY’s financial outlook, investors can access the comprehensive Pro Research Report available on InvestingPro.

Chris Perez, Chief Executive Officer of Axis, stated the partnership "was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve."

BrainsWay specializes in noninvasive neurostimulation treatments for mental health disorders through its Deep TMS platform technology. The company has received three FDA clearances for treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

Axis Integrated Mental Health services mental health practices that combine psychiatry and psychotherapy with advanced treatments including Deep TMS and Spravato.

The information in this article is based on a company press release statement.

In other recent news, BrainsWay reported record net revenue of $12.6 million for the second quarter of 2025, with net earnings of $0.05 per share. The company shipped 88 Deep Transcranial Magnetic Stimulation (Deep TMS) systems during the quarter, marking a 35% increase from the previous year, and bringing the total installed base to 1,522 systems. H.C. Wainwright responded to these results by raising its price target for BrainsWay to $17 from $16 while maintaining a Buy rating. In another development, BrainsWay announced promising preliminary results from a multicenter trial of its accelerated Deep TMS protocol for major depressive disorder, which showed comparable efficacy to standard treatment with fewer clinic visits. The trial involved 104 adult patients across eight sites and included an accelerated protocol with multiple daily sessions. H.C. Wainwright reiterated its Buy rating and $16 price target following this announcement. Additionally, BrainsWay has made a strategic equity investment of $5 million in Stella MSO, LLC, gaining a minority stake in the management services organization that operates over 20 mental health clinics in the U.S. and Israel. This investment is part of BrainsWay’s strategy to expand access to innovative mental health treatments and support interventional psychiatry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.